These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38315762)

  • 1. Aldosterone Synthase Inhibitors and Mineralocorticoid Receptor Antagonists: Competitors or Collaborators?
    Pitt B; Williams GH
    Circulation; 2024 Feb; 149(6):414-416. PubMed ID: 38315762
    [No Abstract]   [Full Text] [Related]  

  • 2. Specific Aldosterone Synthase Inhibition: A Potential Improvement Over Mineralocorticoid Receptor Antagonism?
    Schneider MP; Hilgers KF
    Hypertension; 2017 Jan; 69(1):11-12. PubMed ID: 27872235
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats.
    Huang BS; White RA; Jeng AY; Leenen FH
    Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R994-R1000. PubMed ID: 19118098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of brain aldosterone and mineralocorticoid receptors in aldosterone-salt hypertension in rats.
    Wang HW; Huang BS; Chen A; Ahmad M; White RA; Leenen FH
    Neuroscience; 2016 Feb; 314():90-105. PubMed ID: 26656220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
    Ando H
    Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldosterone synthase inhibitors in cardiovascular and renal diseases.
    Namsolleck P; Unger T
    Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i62-i68. PubMed ID: 24493871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle Cells.
    Alesutan I; Voelkl J; Feger M; Kratschmar DV; Castor T; Mia S; Sacherer M; Viereck R; Borst O; Leibrock C; Gawaz M; Kuro-O M; Pilz S; Tomaschitz A; Odermatt A; Pieske B; Wagner CA; Lang F
    Sci Rep; 2017 May; 7(1):2059. PubMed ID: 28515448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
    Hosoya K; Minakuchi H; Wakino S; Fujimura K; Hasegawa K; Komatsu M; Yoshifuji A; Futatsugi K; Shinozuka K; Washida N; Kanda T; Tokuyama H; Hayashi K; Itoh H
    Kidney Int; 2015 Apr; 87(4):749-60. PubMed ID: 25337775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
    Huang BS; White RA; Ahmad M; Leenen FH
    Hypertension; 2013 Sep; 62(3):564-71. PubMed ID: 23856493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone and inflammation.
    Gilbert KC; Brown NJ
    Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):199-204. PubMed ID: 20422780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of agents that affect aldosterone action.
    Tamargo J; Solini A; Ruilope LM
    Semin Nephrol; 2014 May; 34(3):285-306. PubMed ID: 25016400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    J Clin Endocrinol Metab; 2023 Jul; 108(8):e638-e639. PubMed ID: 36740773
    [No Abstract]   [Full Text] [Related]  

  • 17. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trilostane, FAD286, and the role of aldosterone in the central regulation of blood pressure: focus on "Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats".
    Funder JW
    Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R992-3. PubMed ID: 19225142
    [No Abstract]   [Full Text] [Related]  

  • 19. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
    Forzano I; Mone P; Varzideh F; Jankauskas SS; Kansakar U; De Luca A; Santulli G
    Front Endocrinol (Lausanne); 2022; 13():1097968. PubMed ID: 36568122
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
    Cavallari LH; Groo VL; Viana MA; Dai Y; Patel SR; Stamos TD
    Pharmacotherapy; 2010 Jan; 30(1):1-9. PubMed ID: 20030467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.